Breaking News Instant updates and real-time market news.

AMZN

Amazon.com

$3,007.79 /

+24.315 (+0.81%)

07:40
07/27/20
07/27
07:40
07/27/20
07:40

Amazon.com price target raised to $3,500 from $3,050 at Wedbush

Wedbush analyst Michael Pachter raised the firm's price target on Amazon.com to $3,500 from $3,050 ahead of quarterly results, while keeping an Outperform rating on the shares. The analyst expects significant top-line upside for Q2, but notes that near- and long-term profitability remains difficult to predict. Additionally, Pachter believes that spending on safety-related measures is unlikely to slow down any time soon.

  • 30

    Jul

  • 14

    Sep

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks
Fly Intel: Top five weekend stock stories » 20:11
06/26/22
06/26
20:11
06/26/22
20:11
SAVE

Spirit Airlines

$24.54 /

+0.71 (+2.98%)

, ULCC

Frontier Group

$10.53 /

+0.655 (+6.64%)

, APO

Apollo Global

$51.97 /

+2.035 (+4.08%)

, WBA

Walgreens Boots Alliance

$41.66 /

+0.77 (+1.88%)

, LCID

Lucid Group

$19.21 /

-0.09 (-0.47%)

, TSLA

Tesla

$737.59 /

+31.915 (+4.52%)

, XPEV

XPeng

$35.32 /

+2.31 (+7.00%)

, LI

Li Auto

$40.79 /

+1.56 (+3.98%)

, NIO

Nio

$24.08 /

+1 (+4.33%)

, RIVN

Rivian Automotive

$29.52 /

+0.06 (+0.20%)

, WBD

Warner Bros. Discovery

$14.28 /

+0.155 (+1.10%)

, PARA

Paramount

$25.74 /

+1.21 (+4.93%)

, SBUX

Starbucks

$78.10 /

+2.9 (+3.86%)

, GM

General Motors

$34.83 /

+1.845 (+5.59%)

, CDRE

Cadre

$19.25 /

+0.51 (+2.72%)

, DHI

D.R. Horton

$67.69 /

+0.23 (+0.34%)

, LEN

Lennar

$71.94 /

+1.2 (+1.70%)

, TOL

Toll Brothers

$45.03 /

+0.555 (+1.25%)

, CLF

Cleveland-Cliffs

$16.49 /

+0.82 (+5.23%)

, NUE

Nucor

$111.05 /

+4.99 (+4.70%)

, STZHF

Stelco Holdings

$26.85 /

+1.1 (+4.27%)

, STLD

Steel Dynamics

$68.92 /

+2.9 (+4.39%)

, X

U.S. Steel

$19.85 /

+0.84 (+4.42%)

, CVNA

Carvana

$31.51 /

+2.73 (+9.49%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Spirit Airlines (SAVE) announced that leading independent proxy advisory company Institutional Shareholder Services recommends Spirit stockholders vote FOR the merger agreement with Frontier Group (ULCC), parent company of Frontier Airlines. This recommendation follows a June 3 report from Glass, Lewis & Co., another leading independent proxy advisory company, also recommending that stockholders vote FOR the proposed merger. 2. Reliance Industries is in talks with several global banks to raise as much as $8 billion for its planned leveraged buyout of Walgreens Boots Alliance's (WBA) international arm, Mint's Anirudh Laskar reported. A consortium of Apollo Global (APO) and Reliance made a binding offer for Boots earlier this month that valued Boots at more than $6.1 billion. 3. The issue with Lucid (LCID) is not direct competition; the issue is valuation, Al Root wrote in this week's edition of Barron's. Lucid, with a value of about $29 billion, is priced at more than eight times 2023 sales of $3.5 billion. That's not just expensive relative to Polestar (PSNY) but also to XPeng (XPEV), NIO (NIO), Li Auto (LI), and Rivian Automotive (RIVN)-all EV companies with sales, but no free cash flow yet, that trade for around 2.6 times 2023 sales. The fundamental risk for Lucid-which sold roughly 500 cars in the past two quarters and is expected to sell about 13,000 in 2022-is that volumes will flatten out or decline as the upper end of the EV market gets saturated. That would be very bad news for Lucid's multiple, the author contended. 4. Warner Bros. (WBD) "Elvis" and Paramount's (PARA) "Top Gun: Maverick" tied for the top spot at the domestic box office this weekend with an estimated $30.5M. The winner won't be declared until Monday when final grosses are tallied. "Top Gun: Maverick" enjoyed a boost in its fifth outing as it was rereleased in select Imax and premium large-format screens. Overseas, the movie earned another $44.5M as it joined the billion-dollar club at the global box office. Meanwhile, "Elvis" opened ahead of expectations, earning an A- CinemaScore and a 94% score on Rotten Tomatoes. 5. Starbucks (SBUX), General Motors (GM), Cadre Holdings (CDRE), D.R. Horton (DHI), Lennar (LEN), Toll Brothers (TOL), Cleveland-Cliffs (CLF), Nucor (NUE), Stelco Holdings (STZHF), Steel Dynamics (STLD) and U.S. Steel (X) saw positive mentions in this week's edition of Barron's, while Carvana (CVNA) was mentioned cautiously.

ShowHide Related Items >><<
XPEV XPeng
$35.32 /

+2.31 (+7.00%)

X U.S. Steel
$19.85 /

+0.84 (+4.42%)

WBD Warner Bros. Discovery
$14.28 /

+0.155 (+1.10%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

TSLA Tesla
$737.59 /

+31.915 (+4.52%)

TOL Toll Brothers
$45.03 /

+0.555 (+1.25%)

STLD Steel Dynamics
$68.92 /

+2.9 (+4.39%)

SBUX Starbucks
$78.10 /

+2.9 (+3.86%)

SAVE Spirit Airlines
$24.54 /

+0.71 (+2.98%)

RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

PARA Paramount
$25.74 /

+1.21 (+4.93%)

NUE Nucor
$111.05 /

+4.99 (+4.70%)

NIO Nio
$24.08 /

+1 (+4.33%)

LI Li Auto
$40.79 /

+1.56 (+3.98%)

LEN Lennar
$71.94 /

+1.2 (+1.70%)

LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

GM General Motors
$34.83 /

+1.845 (+5.59%)

DHI D.R. Horton
$67.69 /

+0.23 (+0.34%)

CVNA Carvana
$31.51 /

+2.73 (+9.49%)

CLF Cleveland-Cliffs
$16.49 /

+0.82 (+5.23%)

CDRE Cadre
$19.25 /

+0.51 (+2.72%)

APO Apollo Global
$51.97 /

+2.035 (+4.08%)

SAVE Spirit Airlines
$24.54 /

+0.71 (+2.98%)

06/23/22 Raymond James
Frontier Group upgraded to Outperform from Market Perform at Raymond James
06/10/22 JPMorgan
Spirit Airlines upgraded to Overweight from Neutral at JPMorgan
05/05/22 Deutsche Bank
Spirit Airlines price target lowered to $27 from $38 at Deutsche Bank
04/11/22 MKM Partners
JetBlue upgraded to Neutral at MKM Partners on valuation
ULCC Frontier Group
$10.53 /

+0.655 (+6.64%)

04/06/22 MKM Partners
MKM Partners expects to see 'heavy regulatory pushback' to JetBlue-Spirit deal
APO Apollo Global
$51.97 /

+2.035 (+4.08%)

05/19/22 Deutsche Bank
Apollo Global price target lowered to $90 from $98 at Deutsche Bank
05/06/22 Deutsche Bank
Apollo Global price target raised to $98 from $95 at Deutsche Bank
05/03/22 Wedbush
Carvana price target lowered to $90 from $120 at Wedbush
04/22/22 BMO Capital
Blackstone price target raised to $142 from $124 at BMO Capital
WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

06/25/22 Barclays
Walgreens Boots Alliance price target lowered to $45 from $50 at Barclays
04/12/22 Cowen
Walgreens Boots Alliance price target lowered to $50 from $55 at Cowen
04/05/22 Deutsche Bank
Walgreens price target lowered to $46 from $52 at Deutsche Bank
04/05/22 UBS
Walgreens Boots Alliance price target lowered to $49 from $52 at UBS
LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

06/06/22 Deutsche Bank
Tesla workforce reduction 'direct warning' to industry, says Deutsche Bank
05/09/22 Citi
Lucid Group price target lowered to $36 from $45 at Citi
05/06/22 Morgan Stanley
Lucid production view looks more bull case than base case, says Morgan Stanley
04/25/22 Wells Fargo
Wells says Wolfspeed design win with Lucid further validation of SiC portfolio
TSLA Tesla
$737.59 /

+31.915 (+4.52%)

06/24/22 Credit Suisse
Credit Suisse cuts Tesla cut, sees Q2 deliveries below consensus
06/22/22 Morgan Stanley
Tesla price target lowered to $1,200 from $1,300 at Morgan Stanley
06/15/22 Mizuho
Mizuho likes three electric vehicle stocks into second half rebound
06/14/22 Morgan Stanley
Morgan Stanley says 'very prudent' to shift some Tesla production to Q3 from Q2
XPEV XPeng
$35.32 /

+2.31 (+7.00%)

06/21/22 Citi
XPeng price target raised to $51.59 from $36.70 at Citi
05/24/22 JPMorgan
XPeng price target lowered to $35 from $42 at JPMorgan
05/24/22 Barclays
XPeng price target lowered to $30 from $39 at Barclays
05/24/22 BofA
XPeng price target lowered to $40 from $46 at BofA
LI Li Auto
$40.79 /

+1.56 (+3.98%)

06/21/22 Citi
Li Auto price target raised to $58.60 from $26.80 at Citi
05/11/22 Citi
Li Auto price target lowered to $26.80 from $51.50 at Citi
05/10/22 BofA
Li Auto price target lowered to $33 from $35 at BofA
04/04/22 UBS
Li Auto price target raised to $52 from $47 at UBS
NIO Nio
$24.08 /

+1 (+4.33%)

06/21/22 Citi
Nio price target lowered to $41.10 from $87 at Citi
06/17/22 Morgan Stanley
Nio's recent outperformance has several drivers, says Morgan Stanley
06/15/22 Morgan Stanley
Nio's ES7, SUV upgrades should meet expectations, says Morgan Stanley
RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

06/01/22 DA Davidson
DA Davidson starts Rivian Automotive with sell on headline worries
06/01/22 DA Davidson
Rivian Automotive initiated with an Underperform at DA Davidson
WBD Warner Bros. Discovery
$14.28 /

+0.155 (+1.10%)

06/16/22 JPMorgan
Warner Bros. Discovery reinstated with a Neutral at JPMorgan
06/02/22 Wolfe Research
Warner Bros. Discovery price target lowered to $20 from $30 at Wolfe Research
06/02/22 Wolfe Research
Paramount assumed at Underperform from Outperform at Wolfe Research
05/12/22 Cowen
Warner Bros. Discovery upgraded on management strategy at Cowen
PARA Paramount
$25.74 /

+1.21 (+4.93%)

06/15/22 Evercore ISI
Disney showing good financial discipline with IPL renewal, says Evercore ISI
05/23/22 Citi
Paramount price target lowered to $44 from $47 at Citi
05/04/22 Deutsche Bank
Paramount price target lowered to $43 from $45 at Deutsche Bank
SBUX Starbucks
$78.10 /

+2.9 (+3.86%)

05/09/22 Deutsche Bank
Starbucks price target lowered to $103 from $116 at Deutsche Bank
05/04/22 MKM Partners
Starbucks price target lowered to $98 from $105 at MKM Partners
05/04/22 Morgan Stanley
Starbucks price target lowered to $87 from $94 at Morgan Stanley
05/04/22 Cowen
Starbucks price target lowered to $94 from $115 at Cowen
GM General Motors
$34.83 /

+1.845 (+5.59%)

06/16/22 Goldman Sachs
Goldman left Samsara analyst day with stronger conviction
06/07/22 Morgan Stanley
MP Materials price target raised to $46 from $42 at Morgan Stanley
06/01/22 Goldman Sachs
General Motors price target lowered to $46 from $59 at Goldman Sachs
06/01/22 Citi
General Motors price target lowered to $87 from $98 at Citi
CDRE Cadre
$19.25 /

+0.51 (+2.72%)

06/13/22 B. Riley
Cadre price target raised to $31 from $27 at B. Riley
11/29/21 Lake Street
Cadre initiated with a Buy at Lake Street
11/29/21 B. Riley
Cadre initiated with a Buy, $26 target at B. Riley
11/29/21 Stifel
Cadre initiated with a Hold at Stifel
DHI D.R. Horton
$67.69 /

+0.23 (+0.34%)

06/21/22 Citi
D.R. Horton price target lowered to $73 from $89 at Citi
06/16/22 UBS
D.R. Horton price target lowered to $105 from $151 at UBS
06/08/22 Barclays
D.R. Horton price target lowered to $96 from $104 at Barclays
06/06/22 BTIG
D.R. Horton price target lowered to $97 from $104 at BTIG
LEN Lennar
$71.94 /

+1.2 (+1.70%)

06/22/22 UBS
Lennar price target lowered to $106 from $108 at UBS
06/22/22 KeyBanc
Lennar price target lowered to $60 from $75 at KeyBanc
06/22/22 BTIG
Lennar price target raised to $97 from $92 at BTIG
06/22/22 Wedbush
Lennar price target lowered to $88 from $130 at Wedbush
TOL Toll Brothers
$45.03 /

+0.555 (+1.25%)

06/21/22 Citi
Toll Brothers price target lowered to $44 from $49 at Citi
06/17/22 Wells Fargo
Toll Brothers downgraded to Equal Weight from Overweight at Wells Fargo
06/16/22 UBS
Toll Brothers price target lowered to $59 from $74 at UBS
05/31/22 Raymond James
Toll Brothers price target lowered to $75 from $82 at Raymond James
CLF Cleveland-Cliffs
$16.49 /

+0.82 (+5.23%)

06/14/22 JPMorgan
Cleveland-Cliffs price target lowered to $37 from $43 at JPMorgan
05/31/22 Goldman Sachs
Cleveland-Cliffs price target lowered to $27 from $36 at Goldman Sachs
04/25/22 B. Riley
Cleveland-Cliffs price target raised to $47 from $46 at B. Riley
04/19/22 Credit Suisse
Cleveland-Cliffs price target raised to $37 from $34 at Credit Suisse
NUE Nucor
$111.05 /

+4.99 (+4.70%)

06/14/22 JPMorgan
Nucor price target lowered to $125 from $146 at JPMorgan
05/31/22 Goldman Sachs
Nucor price target lowered to $130 from $148 at Goldman Sachs
05/17/22 BMO Capital
Nucor price target lowered to $128 from $168 at BMO Capital
04/25/22 Argus
Nucor price target raised to $190 from $140 at Argus
STZHF Stelco Holdings
$26.85 /

+1.1 (+4.27%)

06/02/22 Scotiabank
Stelco Holdings price target raised to C$57 from C$53 at Scotiabank
05/09/22 RBC Capital
Stelco Holdings price target raised to C$62 from C$61 at RBC Capital
05/09/22 Scotiabank
Stelco Holdings price target lowered to C$53 from C$56 at Scotiabank
04/14/22 RBC Capital
Stelco Holdings price target raised to C$61 from C$60 at RBC Capital
STLD Steel Dynamics
$68.92 /

+2.9 (+4.39%)

06/14/22 JPMorgan
Steel Dynamics price target lowered to $110 from $129 at JPMorgan
05/31/22 Goldman Sachs
Steel Dynamics downgraded to Neutral from Buy at Goldman Sachs
04/22/22 BMO Capital
Steel Dynamics price target raised to $104 from $95 at BMO Capital
03/24/22 JPMorgan
Steel Dynamics price target raised to $117 from $95 at JPMorgan
X U.S. Steel
$19.85 /

+0.84 (+4.42%)

06/17/22 BMO Capital
U.S. Steel price target lowered to $23 from $30 at BMO Capital
06/17/22 Credit Suisse
U.S. Steel price target lowered to $44 from $49 at Credit Suisse
06/14/22 JPMorgan
U.S. Steel price target lowered to $28 from $34 at JPMorgan
05/31/22 Goldman Sachs
U.S. Steel price target lowered to $22 from $36 at Goldman Sachs
CVNA Carvana
$31.51 /

+2.73 (+9.49%)

06/13/22 Stephens
Carvana price target lowered to $38 from $100 at Stephens
05/19/22 BofA
Carvana price target lowered to $80 from $225 at BofA
05/16/22 Needham
Carvana price target lowered to $80 from $121 at Needham
05/16/22 DA Davidson
Carvana price target lowered to $49 from $140 at DA Davidson
XPEV XPeng
$35.32 /

+2.31 (+7.00%)

X U.S. Steel
$19.85 /

+0.84 (+4.42%)

WBD Warner Bros. Discovery
$14.28 /

+0.155 (+1.10%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

ULCC Frontier Group
$10.53 /

+0.655 (+6.64%)

TSLA Tesla
$737.59 /

+31.915 (+4.52%)

TOL Toll Brothers
$45.03 /

+0.555 (+1.25%)

STLD Steel Dynamics
$68.92 /

+2.9 (+4.39%)

SBUX Starbucks
$78.10 /

+2.9 (+3.86%)

SAVE Spirit Airlines
$24.54 /

+0.71 (+2.98%)

RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

PARA Paramount
$25.74 /

+1.21 (+4.93%)

NUE Nucor
$111.05 /

+4.99 (+4.70%)

NIO Nio
$24.08 /

+1 (+4.33%)

LI Li Auto
$40.79 /

+1.56 (+3.98%)

LEN Lennar
$71.94 /

+1.2 (+1.70%)

LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

GM General Motors
$34.83 /

+1.845 (+5.59%)

DHI D.R. Horton
$67.69 /

+0.23 (+0.34%)

CVNA Carvana
$31.51 /

+2.73 (+9.49%)

CLF Cleveland-Cliffs
$16.49 /

+0.82 (+5.23%)

CDRE Cadre
$19.25 /

+0.51 (+2.72%)

APO Apollo Global
$51.97 /

+2.035 (+4.08%)

  • 10
    Jun
  • 22
    Apr
  • 10
    Nov
  • 13
    Aug
  • 04
    Nov
XPEV XPeng
$35.32 /

+2.31 (+7.00%)

WBD Warner Bros. Discovery
$14.28 /

+0.155 (+1.10%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

ULCC Frontier Group
$10.53 /

+0.655 (+6.64%)

TSLA Tesla
$737.59 /

+31.915 (+4.52%)

SBUX Starbucks
$78.10 /

+2.9 (+3.86%)

SAVE Spirit Airlines
$24.54 /

+0.71 (+2.98%)

RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

PARA Paramount
$25.74 /

+1.21 (+4.93%)

NUE Nucor
$111.05 /

+4.99 (+4.70%)

NIO Nio
$24.08 /

+1 (+4.33%)

LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

GM General Motors
$34.83 /

+1.845 (+5.59%)

DHI D.R. Horton
$67.69 /

+0.23 (+0.34%)

CVNA Carvana
$31.51 /

+2.73 (+9.49%)

CDRE Cadre
$19.25 /

+0.51 (+2.72%)

APO Apollo Global
$51.97 /

+2.035 (+4.08%)

XPEV XPeng
$35.32 /

+2.31 (+7.00%)

X U.S. Steel
$19.85 /

+0.84 (+4.42%)

WBD Warner Bros. Discovery
$14.28 /

+0.155 (+1.10%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

ULCC Frontier Group
$10.53 /

+0.655 (+6.64%)

TSLA Tesla
$737.59 /

+31.915 (+4.52%)

TOL Toll Brothers
$45.03 /

+0.555 (+1.25%)

STLD Steel Dynamics
$68.92 /

+2.9 (+4.39%)

SBUX Starbucks
$78.10 /

+2.9 (+3.86%)

SAVE Spirit Airlines
$24.54 /

+0.71 (+2.98%)

RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

PARA Paramount
$25.74 /

+1.21 (+4.93%)

NUE Nucor
$111.05 /

+4.99 (+4.70%)

NIO Nio
$24.08 /

+1 (+4.33%)

LI Li Auto
$40.79 /

+1.56 (+3.98%)

LEN Lennar
$71.94 /

+1.2 (+1.70%)

LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

GM General Motors
$34.83 /

+1.845 (+5.59%)

DHI D.R. Horton
$67.69 /

+0.23 (+0.34%)

CVNA Carvana
$31.51 /

+2.73 (+9.49%)

CLF Cleveland-Cliffs
$16.49 /

+0.82 (+5.23%)

CDRE Cadre
$19.25 /

+0.51 (+2.72%)

APO Apollo Global
$51.97 /

+2.035 (+4.08%)

XPEV XPeng
$35.32 /

+2.31 (+7.00%)

X U.S. Steel
$19.85 /

+0.84 (+4.42%)

WBD Warner Bros. Discovery
$14.28 /

+0.155 (+1.10%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

TSLA Tesla
$737.59 /

+31.915 (+4.52%)

TOL Toll Brothers
$45.03 /

+0.555 (+1.25%)

STLD Steel Dynamics
$68.92 /

+2.9 (+4.39%)

SBUX Starbucks
$78.10 /

+2.9 (+3.86%)

SAVE Spirit Airlines
$24.54 /

+0.71 (+2.98%)

RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

PARA Paramount
$25.74 /

+1.21 (+4.93%)

NUE Nucor
$111.05 /

+4.99 (+4.70%)

NIO Nio
$24.08 /

+1 (+4.33%)

LI Li Auto
$40.79 /

+1.56 (+3.98%)

LEN Lennar
$71.94 /

+1.2 (+1.70%)

LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

GM General Motors
$34.83 /

+1.845 (+5.59%)

DHI D.R. Horton
$67.69 /

+0.23 (+0.34%)

CVNA Carvana
$31.51 /

+2.73 (+9.49%)

CLF Cleveland-Cliffs
$16.49 /

+0.82 (+5.23%)

CDRE Cadre
$19.25 /

+0.51 (+2.72%)

APO Apollo Global
$51.97 /

+2.035 (+4.08%)

Hot Stocks
Innovent, Lilly say TYVYT approved by China NMPA in combo with chemotherapy » 20:05
06/26/22
06/26
20:05
06/26/22
20:05
LLY

Eli Lilly

$325.67 /

+12.595 (+4.02%)

Innovent Biologics and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LLY Eli Lilly
$325.67 /

+12.595 (+4.02%)

LLY Eli Lilly
$325.67 /

+12.595 (+4.02%)

06/06/22 Mizuho
Weight loss data sets up more upside in Lilly shares, says Mizuho
06/01/22 JPMorgan
Eli Lilly price target raised to $355 from $340 at JPMorgan
05/23/22 SVB Leerink
Eli Lilly initiated with an Outperform at SVB Leerink
05/02/22 Wells Fargo
AbbVie price target raised to $200 from $165 at Wells Fargo
LLY Eli Lilly
$325.67 /

+12.595 (+4.02%)

LLY Eli Lilly
$325.67 /

+12.595 (+4.02%)

LLY Eli Lilly
$325.67 /

+12.595 (+4.02%)

LLY Eli Lilly
$325.67 /

+12.595 (+4.02%)

Periodicals
AT&T, Verizon raise prices, test consumer budgets, WSJ says » 18:13
06/26/22
06/26
18:13
06/26/22
18:13
T

AT&T

$21.00 /

+0.37 (+1.79%)

, VZ

Verizon

$50.97 /

-1.15 (-2.21%)

Wireless companies have…

Wireless companies have spent the past month boosting fees and raising the cost of some midrange wireless plans, The Wall Street Journal's Drew Fitzgerald reports. AT&T (T) starting in June, raised the cost of its older wireless plans by up to $6 for single lines and $12 for family plans, encouraging subscribers to adopt newer unlimited data plans. Verizon (VZ) later matched AT&T with a $6 or $12 monthly price increase on its metered-data plans. It also raised some monthly fees on consumer wireless plans by $1.35 and levied a monthly per-smartphone fee of up to $2.20 on many business plans, the publication notes. Reference Link

ShowHide Related Items >><<
VZ Verizon
$50.97 /

-1.15 (-2.21%)

T AT&T
$21.00 /

+0.37 (+1.79%)

T AT&T
$21.00 /

+0.37 (+1.79%)

06/16/22 Tigress Financial
AT&T price target lowered to $28 from $31 at Tigress Financial
06/02/22 Wolfe Research
AT&T price target lowered to $22 from $27 at Wolfe Research
05/31/22 LightShed Partners
Verizon initiated with a Neutral at LightShed Partners
05/09/22 Benchmark
Dish price target lowered to $37 from $50 at Benchmark
VZ Verizon
$50.97 /

-1.15 (-2.21%)

06/22/22 RBC Capital
Verizon price target lowered to $54 from $57 at RBC Capital
06/21/22 Credit Suisse
Verizon price target lowered to $54 from $58 at Credit Suisse
06/10/22 Truist
Cable One price target raised to $1,600 from $1,400 at Truist
06/02/22 Wolfe Research
Verizon price target lowered to $51 from $60 at Wolfe Research
VZ Verizon
$50.97 /

-1.15 (-2.21%)

T AT&T
$21.00 /

+0.37 (+1.79%)

VZ Verizon
$50.97 /

-1.15 (-2.21%)

T AT&T
$21.00 /

+0.37 (+1.79%)

VZ Verizon
$50.97 /

-1.15 (-2.21%)

T AT&T
$21.00 /

+0.37 (+1.79%)

VZ Verizon
$50.97 /

-1.15 (-2.21%)

T AT&T
$21.00 /

+0.37 (+1.79%)

Periodicals
3M faces potentially billions in liabilities over $7.63 earplugs, WSJ reports » 18:09
06/26/22
06/26
18:09
06/26/22
18:09
MMM

3M

$134.35 /

+4.23 (+3.25%)

More than 100,000 U.S.…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MMM 3M
$134.35 /

+4.23 (+3.25%)

MMM 3M
$134.35 /

+4.23 (+3.25%)

06/16/22 Jefferies
3M price target lowered to $145 from $161 at Jefferies
04/28/22 Argus
3M downgraded to Hold from Buy at Argus
04/28/22 Argus
3M downgraded to Hold from Buy at Argus
04/27/22 Barclays
3M price target lowered to $146 from $155 at Barclays
MMM 3M
$134.35 /

+4.23 (+3.25%)

MMM 3M
$134.35 /

+4.23 (+3.25%)

MMM 3M
$134.35 /

+4.23 (+3.25%)

MMM 3M
$134.35 /

+4.23 (+3.25%)

Periodicals
Tesla. Ford and GM raise EV prices as costs and demand grow, WSJ reports » 18:06
06/26/22
06/26
18:06
06/26/22
18:06
TSLA

Tesla

$737.59 /

+31.915 (+4.52%)

, F

Ford

$12.02 /

+0.465 (+4.02%)

, GM

General Motors

$34.83 /

+1.845 (+5.59%)

, RIVN

Rivian Automotive

$29.52 /

+0.06 (+0.20%)

, LCID

Lucid Group

$19.21 /

-0.09 (-0.47%)

Auto makers have been…

Auto makers have been raising prices on electric cars, partly to offset the soaring cost of materials used in their large batteries. Car executives also are capitalizing on strong consumer interest in EVs, as a new wave of plug-in vehicles hits the market, The Wall Street Journal's Mike Colias reports. In the past few months, Tesla (TSLA), Ford (F), General Motors (GM), Rivian Automotive (RIVN) and Lucid Group (LCID) have increased prices on certain electric models, the author notes. Reference Link

ShowHide Related Items >><<
TSLA Tesla
$737.59 /

+31.915 (+4.52%)

RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

GM General Motors
$34.83 /

+1.845 (+5.59%)

F Ford
$12.02 /

+0.465 (+4.02%)

TSLA Tesla
$737.59 /

+31.915 (+4.52%)

06/24/22 Credit Suisse
Credit Suisse cuts Tesla cut, sees Q2 deliveries below consensus
06/22/22 Morgan Stanley
Tesla price target lowered to $1,200 from $1,300 at Morgan Stanley
06/15/22 Mizuho
Mizuho likes three electric vehicle stocks into second half rebound
06/14/22 Morgan Stanley
Morgan Stanley says 'very prudent' to shift some Tesla production to Q3 from Q2
F Ford
$12.02 /

+0.465 (+4.02%)

06/01/22 Goldman Sachs
Ford price target lowered to $14 from $18 at Goldman Sachs
06/01/22 Citi
Citi lowers Ford tagret but opens '90-Day Upside Catalyst Watch'
05/20/22 Tigress Financial
Ford price target raised to $22 from $20 at Tigress Financial
05/13/22 Morgan Stanley
Ford upgraded to Equal Weight at Morgan Stanley following selloff
GM General Motors
$34.83 /

+1.845 (+5.59%)

06/16/22 Goldman Sachs
Goldman left Samsara analyst day with stronger conviction
06/07/22 Morgan Stanley
MP Materials price target raised to $46 from $42 at Morgan Stanley
06/01/22 Goldman Sachs
General Motors price target lowered to $46 from $59 at Goldman Sachs
06/01/22 Citi
General Motors price target lowered to $87 from $98 at Citi
RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

06/06/22 Deutsche Bank
Tesla workforce reduction 'direct warning' to industry, says Deutsche Bank
06/01/22 DA Davidson
DA Davidson starts Rivian Automotive with sell on headline worries
06/01/22 DA Davidson
Rivian Automotive initiated with an Underperform at DA Davidson
LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

05/09/22 Citi
Lucid Group price target lowered to $36 from $45 at Citi
05/06/22 Morgan Stanley
Lucid production view looks more bull case than base case, says Morgan Stanley
04/25/22 Wells Fargo
Wells says Wolfspeed design win with Lucid further validation of SiC portfolio
TSLA Tesla
$737.59 /

+31.915 (+4.52%)

RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

GM General Motors
$34.83 /

+1.845 (+5.59%)

F Ford
$12.02 /

+0.465 (+4.02%)

  • 10
    Nov
TSLA Tesla
$737.59 /

+31.915 (+4.52%)

RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

GM General Motors
$34.83 /

+1.845 (+5.59%)

F Ford
$12.02 /

+0.465 (+4.02%)

TSLA Tesla
$737.59 /

+31.915 (+4.52%)

RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

GM General Motors
$34.83 /

+1.845 (+5.59%)

F Ford
$12.02 /

+0.465 (+4.02%)

TSLA Tesla
$737.59 /

+31.915 (+4.52%)

RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

GM General Motors
$34.83 /

+1.845 (+5.59%)

F Ford
$12.02 /

+0.465 (+4.02%)

Periodicals
Reliance in talks to raise up to $8B for Boots, Mint reports » 18:03
06/26/22
06/26
18:03
06/26/22
18:03
WBA

Walgreens Boots Alliance

$41.66 /

+0.77 (+1.88%)

, APO

Apollo Global

$51.97 /

+2.035 (+4.08%)

Reliance Industries is in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

APO Apollo Global
$51.97 /

+2.035 (+4.08%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

06/25/22 Barclays
Walgreens Boots Alliance price target lowered to $45 from $50 at Barclays
04/12/22 Cowen
Walgreens Boots Alliance price target lowered to $50 from $55 at Cowen
04/05/22 Deutsche Bank
Walgreens price target lowered to $46 from $52 at Deutsche Bank
04/05/22 UBS
Walgreens Boots Alliance price target lowered to $49 from $52 at UBS
APO Apollo Global
$51.97 /

+2.035 (+4.08%)

05/19/22 Deutsche Bank
Apollo Global price target lowered to $90 from $98 at Deutsche Bank
05/06/22 Deutsche Bank
Apollo Global price target raised to $98 from $95 at Deutsche Bank
05/03/22 Wedbush
Carvana price target lowered to $90 from $120 at Wedbush
04/22/22 BMO Capital
Blackstone price target raised to $142 from $124 at BMO Capital
WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

APO Apollo Global
$51.97 /

+2.035 (+4.08%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

APO Apollo Global
$51.97 /

+2.035 (+4.08%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

APO Apollo Global
$51.97 /

+2.035 (+4.08%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

APO Apollo Global
$51.97 /

+2.035 (+4.08%)

On The Fly
Box Office Battle: ‘Elvis’ ties with ‘Top Gun: Maverick’ for top spot » 17:32
06/26/22
06/26
17:32
06/26/22
17:32
WBD

Warner Bros. Discovery

$14.28 /

+0.155 (+1.10%)

, CMCSA

Comcast

$39.58 /

+0.485 (+1.24%)

, CMCSK

Comcast

$58.00 /

+ (+0.00%)

, SONY

Sony

$85.67 /

+1.89 (+2.26%)

, LGF.A

Lionsgate

$10.05 /

+0.63 (+6.69%)

, LGF.B

Lionsgate

$9.62 /

+0.605 (+6.71%)

, DIS

Disney

$97.77 /

+3.42 (+3.62%)

, PARA

Paramount

$25.74 /

+1.21 (+4.93%)

"Box Office Battle" is…

ShowHide Related Items >><<
WBD Warner Bros. Discovery
$14.28 /

+0.155 (+1.10%)

SONY Sony
$85.67 /

+1.89 (+2.26%)

PARA Paramount
$25.74 /

+1.21 (+4.93%)

LGF.A Lionsgate
$10.05 /

+0.63 (+6.69%)

DIS Disney
$97.77 /

+3.42 (+3.62%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$39.58 /

+0.485 (+1.24%)

WBD Warner Bros. Discovery
$14.28 /

+0.155 (+1.10%)

06/16/22 JPMorgan
Warner Bros. Discovery reinstated with a Neutral at JPMorgan
06/02/22 Wolfe Research
Warner Bros. Discovery price target lowered to $20 from $30 at Wolfe Research
06/02/22 Wolfe Research
Paramount assumed at Underperform from Outperform at Wolfe Research
05/12/22 Cowen
Warner Bros. Discovery upgraded on management strategy at Cowen
CMCSA Comcast
$39.58 /

+0.485 (+1.24%)

06/21/22 Truist
Magnite well positioned to partner with Netflix, says Truist
06/17/22 TD Securities
Cogeco Communications upgraded to Buy from Hold at TD Securities
06/02/22 Wolfe Research
Comcast assumed at Peer Perform from Outperform at Wolfe Research
06/02/22 Benchmark
Comcast price target lowered to $60 from $65 at Benchmark
CMCSK Comcast
$58.00 /

+ (+0.00%)

05/23/22 Raymond James
Electronic Arts moves 'somewhat unexpected,' says Raymond James
04/14/22 Oppenheimer
Comcast price target lowered to $60 from $75 at Oppenheimer
03/23/22 Craig-Hallum
ComScore poised for share gains in local measurement, says Craig-Hallum
SONY Sony
$85.67 /

+1.89 (+2.26%)

05/18/22 Oppenheimer
Sony price target lowered to $125 from $150 at Oppenheimer
04/13/22 CLSA
Sony downgraded to Outperform from Buy at CLSA
03/08/22 Benchmark
Take-Two next-gen 'GTA' ports to have lower price point, says Benchmark
02/07/22 Morgan Stanley
Morgan Stanley upgrades TSMC to Overweight, looking beyond current correction
LGF.A Lionsgate
$10.05 /

+0.63 (+6.69%)

06/03/22 Deutsche Bank
Lionsgate price target lowered to $13 from $16 at Deutsche Bank
06/02/22 Wolfe Research
Lionsgate initiated with an Outperform at Wolfe Research
04/19/22 Rosenblatt
Lionsgate initiated with a Buy at Rosenblatt
02/07/22 Cowen
Lionsgate price target lowered to $17 from $21 at Cowen
LGF.B Lionsgate
$9.62 /

+0.605 (+6.71%)

01/31/22 Truist
Lionsgate price target raised to $18 from $16 at Truist
01/04/22 Wells Fargo
Wells Fargo upgrades Lionsgate to Overweight, raises price target to $25
DIS Disney
$97.77 /

+3.42 (+3.62%)

06/15/22 Evercore ISI
Disney showing good financial discipline with IPL renewal, says Evercore ISI
06/06/22 Deutsche Bank
Disney price target lowered to $130 from $191 at Deutsche Bank
06/03/22 Needham
Needham raises Disney earnings estimate on Parks segment strength
06/02/22 Wolfe Research
Disney price target lowered to $128 from $211 at Wolfe Research
PARA Paramount
$25.74 /

+1.21 (+4.93%)

05/23/22 Citi
Paramount price target lowered to $44 from $47 at Citi
05/04/22 Deutsche Bank
Paramount price target lowered to $43 from $45 at Deutsche Bank
WBD Warner Bros. Discovery
$14.28 /

+0.155 (+1.10%)

SONY Sony
$85.67 /

+1.89 (+2.26%)

PARA Paramount
$25.74 /

+1.21 (+4.93%)

LGF.A Lionsgate
$10.05 /

+0.63 (+6.69%)

DIS Disney
$97.77 /

+3.42 (+3.62%)

CMCSA Comcast
$39.58 /

+0.485 (+1.24%)

WBD Warner Bros. Discovery
$14.28 /

+0.155 (+1.10%)

SONY Sony
$85.67 /

+1.89 (+2.26%)

PARA Paramount
$25.74 /

+1.21 (+4.93%)

LGF.B Lionsgate
$9.62 /

+0.605 (+6.71%)

LGF.A Lionsgate
$10.05 /

+0.63 (+6.69%)

DIS Disney
$97.77 /

+3.42 (+3.62%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$39.58 /

+0.485 (+1.24%)

WBD Warner Bros. Discovery
$14.28 /

+0.155 (+1.10%)

SONY Sony
$85.67 /

+1.89 (+2.26%)

LGF.A Lionsgate
$10.05 /

+0.63 (+6.69%)

DIS Disney
$97.77 /

+3.42 (+3.62%)

CMCSA Comcast
$39.58 /

+0.485 (+1.24%)

WBD Warner Bros. Discovery
$14.28 /

+0.155 (+1.10%)

PARA Paramount
$25.74 /

+1.21 (+4.93%)

DIS Disney
$97.77 /

+3.42 (+3.62%)

CMCSA Comcast
$39.58 /

+0.485 (+1.24%)

Hot Stocks
ISS recommends Spirit holders vote for amended merger agreement with Frontier » 16:55
06/26/22
06/26
16:55
06/26/22
16:55
SAVE

Spirit Airlines

$24.54 /

+0.71 (+2.98%)

, ULCC

Frontier Group

$10.53 /

+0.655 (+6.64%)

, JBLU

JetBlue

$8.61 /

+0.465 (+5.71%)

Spirit Airlines (SAVE)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ULCC Frontier Group
$10.53 /

+0.655 (+6.64%)

SAVE Spirit Airlines
$24.54 /

+0.71 (+2.98%)

JBLU JetBlue
$8.61 /

+0.465 (+5.71%)

SAVE Spirit Airlines
$24.54 /

+0.71 (+2.98%)

06/23/22 Raymond James
Frontier Group upgraded to Outperform from Market Perform at Raymond James
06/10/22 JPMorgan
Spirit Airlines upgraded to Overweight from Neutral at JPMorgan
05/05/22 Deutsche Bank
Spirit Airlines price target lowered to $27 from $38 at Deutsche Bank
04/11/22 MKM Partners
JetBlue upgraded to Neutral at MKM Partners on valuation
ULCC Frontier Group
$10.53 /

+0.655 (+6.64%)

04/06/22 MKM Partners
MKM Partners expects to see 'heavy regulatory pushback' to JetBlue-Spirit deal
JBLU JetBlue
$8.61 /

+0.465 (+5.71%)

04/26/22 JPMorgan
JetBlue double downgraded to Underweight from Overweight at JPMorgan
04/22/22 Deutsche Bank
JetBlue downgraded to Hold on headwinds at Deutsche Bank
ULCC Frontier Group
$10.53 /

+0.655 (+6.64%)

SAVE Spirit Airlines
$24.54 /

+0.71 (+2.98%)

JBLU JetBlue
$8.61 /

+0.465 (+5.71%)

ULCC Frontier Group
$10.53 /

+0.655 (+6.64%)

SAVE Spirit Airlines
$24.54 /

+0.71 (+2.98%)

ULCC Frontier Group
$10.53 /

+0.655 (+6.64%)

SAVE Spirit Airlines
$24.54 /

+0.71 (+2.98%)

SAVE Spirit Airlines
$24.54 /

+0.71 (+2.98%)

JBLU JetBlue
$8.61 /

+0.465 (+5.71%)

Hot Stocks
Madrigal Pharmaceuticals presents late-breaking Phase 3 NASH data » 16:49
06/26/22
06/26
16:49
06/26/22
16:49
MDGL

Madrigal Pharmaceuticals

$83.50 /

-1.14 (-1.35%)

Madrigal Pharmaceuticals…

Madrigal Pharmaceuticals announced data from multiple resmetirom abstracts presented at the European Association for the Study of the Liver's International Liver Congress, including a late-breaking presentation of data from the Phase 3 MAESTRO-NAFLD-1 study and three additional oral presentations from the resmetirom clinical development program. Primary and key secondary endpoints from the double-blind, placebo-controlled, 969-patient MAESTRO-NAFLD-1 safety study were achieved; resmetirom was safe and well tolerated and provided significant reductions in liver fat, LDL-C, and other atherogenic lipids vs placebo. Patients treated with resmetirom also achieved significant reductions relative to placebo in ALT, AST, and GGT. For those patients with sufficient baseline liver stiffness, as measured by FibroScan vibration-controlled transient elastography or magnetic resonance elastography, responder analyses showed statistically significant VCTE and MRE responses in the resmetirom groups compared to placebo. Adverse event-related withdrawals were uncommon in the MAESTRO-NAFLD-1 study. The most common adverse event reported with greater frequency in the resmetirom groups vs placebo was generally mild diarrhea or increased stool frequency at the beginning of therapy. 105 patients with well-compensated NASH cirrhosis were enrolled in the open-label arm of the MAESTRO-NAFLD-1 study. Baseline FibroScan VCTE and MRE scores were consistent with F4 fibrosis. Patients with lower MRI-PDFF at baseline had more progressed cirrhosis and greater spleen volumes. Similar to patients with non-cirrhotic NASH, liver volume was greatly elevated compared to normal at baseline. Resmetirom reduced MRI-PDFF and LDL-C and other atherogenic lipids in patients with NASH cirrhosis and reduced FibroScan controlled attenuation parameter, VCTE, and MRE in a significant fraction of patients. The largest reduction in FibroScan VCTE occurred in the more advanced group. Similar improvements were observed in MRE. 73% of patients, independent of baseline cirrhosis severity, had at least 15% reduction in liver volume at Week 52. Spleen volume was also reduced and was strongly correlated with liver volume change and exposure to resmetirom. Reductions in liver enzymes and atherogenic lipids were similar across patient subgroups. Resmetirom was safe and well tolerated. As observed in patients with noncirrhotic NASH, mild GI adverse events were seen at the beginning of therapy. No differences in safety parameters between patients with cirrhosis compared to noncirrhotic NASH patients were noted. No thyroid axis changes or hyper- or hypothyroid symptoms were observed. Abstracts from the resmetirom development program provide new insights to inform noninvasive testing strategies, improve artificial intelligence-based evaluation of treatment response, and better characterize the cost burden of NASH.

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$83.50 /

-1.14 (-1.35%)

MDGL Madrigal Pharmaceuticals
$83.50 /

-1.14 (-1.35%)

05/12/22 Canaccord
Madrigal Pharmaceuticals price target raised to $151 from $133 at Canaccord
05/10/22 Oppenheimer
Madrigal Pharmaceuticals price target lowered to $170 from $180 at Oppenheimer
02/25/22 H.C. Wainwright
H.C. Wainwright 'unfazed' by Madrigal's 'minor delay' in pivotal data readout
01/31/22 B. Riley
Madrigal data 'somewhat helps alleviate' safety concerns, says B. Riley
MDGL Madrigal Pharmaceuticals
$83.50 /

-1.14 (-1.35%)

Hot Stocks
Vir Biotechnology announces new clinical data from broad Hepatitis B program » 16:42
06/26/22
06/26
16:42
06/26/22
16:42
VIR

Vir Biotechnology

$24.76 /

-1.1 (-4.25%)

, GILD

Gilead

$63.08 /

+0.5 (+0.80%)

Vir Biotechnology (VIR)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VIR Vir Biotechnology
$24.76 /

-1.1 (-4.25%)

GILD Gilead
$63.08 /

+0.5 (+0.80%)

VIR Vir Biotechnology
$24.76 /

-1.1 (-4.25%)

05/12/22 H.C. Wainwright
Vir Biotechnology price target lowered to $125 from $250 at H.C. Wainwright
03/31/22 H.C. Wainwright
H.C. Wainwright says data support Vir 'multi-blockbuster' HBV program potential
03/30/22 H.C. Wainwright
Vir Biotechnology price target lowered to $200 from $300 at H.C. Wainwright
03/28/22 Needham
Vir Biotechnology price target lowered to $45 from $80 at Needham
GILD Gilead
$63.08 /

+0.5 (+0.80%)

06/06/22 Stifel
ALX Oncology price target lowered to $16 from $35 at Stifel
06/03/22 Piper Sandler
ALX's evorpacept best-in-class aong CD47-targeting agents, says Piper Sandler
05/23/22 SVB Leerink
Gilead initiated with a Market Perform at SVB Leerink
05/17/22 BMO Capital
Scholar Rock price target lowered to $55 from $74 at BMO Capital
VIR Vir Biotechnology
$24.76 /

-1.1 (-4.25%)

GILD Gilead
$63.08 /

+0.5 (+0.80%)

GILD Gilead
$63.08 /

+0.5 (+0.80%)

VIR Vir Biotechnology
$24.76 /

-1.1 (-4.25%)

GILD Gilead
$63.08 /

+0.5 (+0.80%)

GILD Gilead
$63.08 /

+0.5 (+0.80%)

Hot Stocks
Arbutus presents new data on AB-729, AB-836 and AB-101 at EASL ILC » 16:39
06/26/22
06/26
16:39
06/26/22
16:39
ABUS

Arbutus Biopharma

$2.84 /

-0.08 (-2.74%)

Arbutus Biopharma…

Arbutus Biopharma announced the presentation of new clinical and pre-clinical data from its proprietary compounds at the European Association for the Study of the Liver International Liver Congress. The new clinical data for AB-729, its RNAi therapeutic, continues to support its development as a potential cornerstone agent for the treatment of chronic hepatitis B infection. In addition, when AB-729 and nucleos(t)ide analogues were discontinued in the first five patients who met stopping criteria and consented, there was no evidence of virologic or clinical relapse in at least 8-24 weeks of follow-up, which may lead to a functional cure. AB-836, its oral capsid inhibitor, demonstrated robust antiviral activity, however, two patients in the 200 mg cohort experienced alanine aminotransferase elevations. Based on these observations along with potentially correlated immunological findings, the company plans to conduct a Phase 1 clinical trial in healthy volunteers before progressing this program. Professor Man-Fung Yuen, Deputy Head of Department, Chief of Division of Gastroenterology and Hepatology, Master of Lap Chee, University of Hong Kong, and lead investigator of AB-729-001 clinical trial, presented a poster titled, "Continued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729". This presentation focused on the preliminary safety and virology data from those patients in part 3 of the AB-729-001 clinical trial who completed treatment with AB-729 and, after meeting the protocol-defined criteria, elected to stop their NA-therapy. Prof. Yuen reported on the first five of the nine patients that had between 8 and 24 weeks of data following discontinuation of all treatment. The mean HBsAg for the five patients at baseline was 2887 IU/mL compared to 69 IU/mL at the last visit after discontinuing all treatment. All five patients remain off all treatment, and all have HBsAg levels below pre-baseline levels. None of the patients have met clinical or virologic relapse criteria. There were no adverse events reported, no ALT elevations observed, and HBV DNA levels remain either less than the LLOQ or have transiently risen and subsequently decreased without intervention. Prof. Yuen also presented data from a poster titled, "Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects." In addition, Prof. Yuen presented follow-up data on Cohort G, which included HBV DNA+ patients who began treatment with tenofovir disoproxil fumarate concurrently with AB-729, and Cohorts E, F, I and J, which enrolled HBeAg- and HBV DNA- patients and evaluated different doses and dosing intervals. Prof. Edward Gane, University of Auckland, New Zealand Liver Transplant Unit, Auckland, New Zealand, presented the full data from this trial in a poster titled, "Safety, tolerability, pharmacokinetics, and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects and subjects with chronic hepatitis B." AB-836-001 is a Phase 1a/1b clinical trial evaluating the safety and tolerability of multiple doses of AB-836 in patients with cHBV infection. Data from part 3 of the trial showed that the 100mg and 200mg doses of AB-836 provided potent inhibition of HBV replication with mean declines in HBV DNA at Day 28 of 3.04 and 3.55 log10 IU/mL, respectively. From a safety standpoint, there were no deaths or SAEs observed. Two HBeAg+ patients in the 100mg dose cohort had transient Grade 3 ALT elevations that resolved with continued dosing and were not considered treatment emergent adverse events. Two patients in the 200mg cohort had Grade 3 and Grade 4 ALT elevations on the last day of dosing that returned to baseline during follow up which were reported as TEAEs. The Grade 3 and Grade 4 ALT elevations seen in the 200 mg cohort were accompanied by serum IP-10 increases, a cytokine previously described to be associated with potential liver toxicity in the capsid inhibitor space. All patients with ALT elevations were asymptomatic and none had changes in bilirubin or met drug-induced liver injury criteria. There were no other clinically significant lab abnormalities, ECG or vital sign changes observed. Dr. Emily Thi presented data from a poster titled, "Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients." The purpose of this study was to assess the preclinical activity of AB-101 and the compound's ability to reinvigorate patient HBV-specific T-cells. Studies were conducted using a transgenic MC38 tumor mouse model and peripheral blood mononuclear cells from cHBV patients. The data presented showed that once daily oral administration of AB-101 resulted in profound tumor reduction that was associated with T-cell activation. In addition, AB-101 activates and reinvigorates HBV-specific T-cells. This favorable preclinical profile supports further development of AB-101 as a therapeutic modality for cHBV treatment. AB-101 is currently undergoing IND-enabling activities.

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$2.84 /

-0.08 (-2.74%)

ABUS Arbutus Biopharma
$2.84 /

-0.08 (-2.74%)

03/14/22 H.C. Wainwright
Arbutus Biopharma price target raised to $8.50 from $8 at H.C. Wainwright
03/04/22 Chardan
Arbutus Biopharma price target raised to $6 from $5.50 at Chardan
12/29/21 Jefferies
Arbutus Biopharma assumed with a Hold at Jefferies
12/13/21 H.C. Wainwright
H.C. Wainwright sees Arbutus' $300M-plus licensing deal for AB-729 as low-risk
ABUS Arbutus Biopharma
$2.84 /

-0.08 (-2.74%)

ABUS Arbutus Biopharma
$2.84 /

-0.08 (-2.74%)

ABUS Arbutus Biopharma
$2.84 /

-0.08 (-2.74%)

Hot Stocks
Immunocore announces initial data from Phase 1 ImmTAV trial » 16:28
06/26/22
06/26
16:28
06/26/22
16:28
IMCR

Immunocore

$35.17 /

-2.295 (-6.13%)

Immunocore announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IMCR Immunocore
$35.17 /

-2.295 (-6.13%)

IMCR Immunocore
$35.17 /

-2.295 (-6.13%)

02/08/22 H.C. Wainwright
Immunocore initiated with a Buy at H.C. Wainwright
11/11/21 JPMorgan
Immunocore share catalysts are 'picking up,' says JPMorgan
10/19/21 Oppenheimer
Immunocore initiated with an Outperform at Oppenheimer
IMCR Immunocore
$35.17 /

-2.295 (-6.13%)

Hot Stocks
Sinovac Biotech COVID-19 vaccine conditionally registered in South Africa » 16:15
06/26/22
06/26
16:15
06/26/22
16:15
SVA

Sinovac Biotech

$6.55 /

+ (+0.00%)

Sinovac Biotech announced…

Sinovac Biotech announced that the South African Health Products Regulatory Authority granted conditional registration to SINOVAC CoronaVac in aged 18 and above adults, based on acceptable safety, quality, and efficacy data submitted. The vaccine is administered intramuscularly in two doses with a 14 to 28-day interval. The CoronaVac was previously authorized for emergency use with conditions by the SAHPRA on July 3, 2021.

ShowHide Related Items >><<
SVA Sinovac Biotech
$6.55 /

+ (+0.00%)

SVA Sinovac Biotech
$6.55 /

+ (+0.00%)

Downgrade
Nayuki downgraded to Sell from Neutral at Goldman Sachs » 14:51
06/26/22
06/26
14:51
06/26/22
14:51
NYKHF

Nayuki

/

+

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NYKHF Nayuki
/

+

04/27/22 Goldman Sachs
Nayuki initiated with a Neutral at Goldman Sachs
Downgrade
Shimao Services downgraded to Sell from Buy at Goldman Sachs » 14:48
06/26/22
06/26
14:48
06/26/22
14:48
SHMSF

Shimao Services

/

+

Goldman Sachs analyst Yi…

Goldman Sachs analyst Yi Wang double downgraded Shimao Services to Sell from Buy with a HK$3.60 price target, suggesting 14% downside. The analyst thinks Shimao's valuation recovery potential will be "pressed by the lingering liquidity pressure" of its parent, which looks unlikely to be removed by the moderate market recovery expected in the coming year.

Conference/Events
R1 RCM to host conference call » 01:03
06/26/22
06/26
01:03
06/26/22
01:03
RCM

R1 RCM

$21.67 /

+0.63 (+2.99%)

Conference call to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RCM R1 RCM
$21.67 /

+0.63 (+2.99%)

RCM R1 RCM
$21.67 /

+0.63 (+2.99%)

05/10/22 Deutsche Bank
R1 RCM price target lowered to $28 from $30 at Deutsche Bank
04/13/22 Guggenheim
R1 RCM initiated with a Neutral at Guggenheim
03/03/22 Baird
R1 RCM price target raised to $32 from $29 at Baird
02/09/22 Deutsche Bank
R1 RCM initiated with a Buy at Deutsche Bank
RCM R1 RCM
$21.67 /

+0.63 (+2.99%)

Conference/Events
Thor Industries to host investor day » 00:36
06/26/22
06/26
00:36
06/26/22
00:36
THO

Thor Industries

$79.39 /

+2.83 (+3.70%)

Investor Day to be held…

Investor Day to be held in Jackson Center, Ohio on June 27 at 9 am. Webcast Link

ShowHide Related Items >><<
THO Thor Industries
$79.39 /

+2.83 (+3.70%)

THO Thor Industries
$79.39 /

+2.83 (+3.70%)

06/09/22 Baird
Thor Industries price target lowered to $100 from $120 at Baird
05/19/22 DA Davidson
Thor Industries cut to Underperform at DA Davidson amid retail weakness
05/19/22 DA Davidson
Thor Industries downgraded to Underperform from Neutral at DA Davidson
05/16/22 BMO Capital
Thor Industries price target lowered to $95 from $110 at BMO Capital
THO Thor Industries
$79.39 /

+2.83 (+3.70%)

THO Thor Industries
$79.39 /

+2.83 (+3.70%)

Conference/Events
One Stop Systems participates in a conference call with Benchmark » 00:31
06/26/22
06/26
00:31
06/26/22
00:31
OSS

One Stop Systems

$3.96 /

-0.02 (-0.50%)

Semiconductor Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OSS One Stop Systems
$3.96 /

-0.02 (-0.50%)

OSS One Stop Systems
$3.96 /

-0.02 (-0.50%)

08/16/21 Benchmark
One Stop Systems assumed with a Buy at Benchmark
07/07/21
Fly Intel: Top five analyst initiations
07/07/21 Lake Street
One Stop Systems initiated with a Buy at Lake Street
OSS One Stop Systems
$3.96 /

-0.02 (-0.50%)

OSS One Stop Systems
$3.96 /

-0.02 (-0.50%)

Conference/Events
Relay Therapeutics to hold virtual event » 16:58
06/25/22
06/25
16:58
06/25/22
16:58
RLAY

Relay Therapeutics

$20.87 /

+1.87 (+9.84%)

Virtual Investor and…

Virtual Investor and Analyst Event to be held on June 27 at 8 am. Webcast Link

ShowHide Related Items >><<
RLAY Relay Therapeutics
$20.87 /

+1.87 (+9.84%)

RLAY Relay Therapeutics
$20.87 /

+1.87 (+9.84%)

06/06/22 Jefferies
Relay Therapeutics initiated with an Underperform at Jefferies
05/10/22 H.C. Wainwright
Relay Therapeutics price target lowered to $47 from $54 at H.C. Wainwright
05/09/22 JMP Securities
Relay Therapeutics price target lowered to $35 from $50 at JMP Securities
02/01/22 Berenberg
Relay Therapeutics initiated with a Buy at Berenberg
RLAY Relay Therapeutics
$20.87 /

+1.87 (+9.84%)

  • 13
    Oct
Conference/Events
Qurate Retail to hold a virtual investor event » 16:54
06/25/22
06/25
16:54
06/25/22
16:54
QRTEA

Qurate Retail

$3.43 /

+0.015 (+0.44%)

CEO Rawlinson holds a…

CEO Rawlinson holds a Virtual Investor Event to be held on June 27 at 9:30 am. Webcast Link

ShowHide Related Items >><<
QRTEA Qurate Retail
$3.43 /

+0.015 (+0.44%)

QRTEA Qurate Retail
$3.43 /

+0.015 (+0.44%)

02/28/22 BofA
Qurate Retail cut to Neutral at BofA amid competitive and execution issues
02/28/22 BofA
Qurate Retail downgraded to Neutral from Buy at BofA
QRTEA Qurate Retail
$3.43 /

+0.015 (+0.44%)

Recommendations
Accenture price target lowered to $370 from $455 at Barclays » 12:41
06/25/22
06/25
12:41
06/25/22
12:41
ACN

Accenture

$299.36 /

+13.3 (+4.65%)

Barclays analyst Ramsey…

Barclays analyst Ramsey El-Assal lowered the firm's price target on Accenture to $370 from $455 and keeps an Overweight rating on the shares following the fiscal Q3 results. The analyst reduced Accenture's valuation multiple saying market multiples for companies in the IT Services sector have compressed materially.

ShowHide Related Items >><<
ACN Accenture
$299.36 /

+13.3 (+4.65%)

ACN Accenture
$299.36 /

+13.3 (+4.65%)

06/24/22 RBC Capital
Accenture price target lowered to $357 from $435 at RBC Capital
06/24/22 Cowen
Accenture price target lowered to $325 from $330 at Cowen
06/24/22 Baird
Accenture price target lowered to $310 from $340 at Baird
06/24/22 Morgan Stanley
Accenture price target lowered to $385 from $390 at Morgan Stanley
ACN Accenture
$299.36 /

+13.3 (+4.65%)

ACN Accenture
$299.36 /

+13.3 (+4.65%)

ACN Accenture
$299.36 /

+13.3 (+4.65%)

Recommendations
Zendesk price target lowered to $77.50 from $128 at UBS » 11:02
06/25/22
06/25
11:02
06/25/22
11:02
ZEN

Zendesk

$74.05 /

+16.03 (+27.63%)

UBS analyst Taylor…

UBS analyst Taylor McGinnis lowered the firm's price target on Zendesk to $77.50 from $128 and keeps a Neutral rating on the shares. The analyst cited the company's announcement that it entered into a definitive agreement to be acquired for $77.50/share.

ShowHide Related Items >><<
ZEN Zendesk
$74.05 /

+16.03 (+27.63%)

ZEN Zendesk
$74.05 /

+16.03 (+27.63%)

06/24/22 Stifel
Stifel keeps Buy rating on Zendesk, doesn't see 'end of the road quite yet'
06/24/22 Canaccord
Zendesk downgraded to Hold from Buy at Canaccord
06/24/22 Jefferies
Competing Zendesk bid 'possible, but not probable,' says Jefferies
06/24/22 Piper Sandler
Zendesk deal premium 'appears underwhelming,' says Piper Sandler
ZEN Zendesk
$74.05 /

+16.03 (+27.63%)

ZEN Zendesk
$74.05 /

+16.03 (+27.63%)

ZEN Zendesk
$74.05 /

+16.03 (+27.63%)

ZEN Zendesk
$74.05 /

+16.03 (+27.63%)

Recommendations
Walgreens Boots Alliance price target lowered to $45 from $50 at Barclays » 10:58
06/25/22
06/25
10:58
06/25/22
10:58
WBA

Walgreens Boots Alliance

$41.66 /

+0.77 (+1.88%)

Barclays analyst Steve…

Barclays analyst Steve Valiquette lowered the firm's price target on Walgreens Boots Alliance to $45 from $50 and keeps an Equal Weight rating on the shares. With a number of perceived overhangs on the retail segment going into the remainder of the year, focus for Walgreens' Q3 print will be on the outlook for foot traffic and front-end inventory/supply chain risk, the analyst said in a research note on Friday. For Q3 itself, Valiquette projects EPS of 88c versus Street view of 93c.

ShowHide Related Items >><<
WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

04/12/22 Cowen
Walgreens Boots Alliance price target lowered to $50 from $55 at Cowen
04/05/22 Deutsche Bank
Walgreens price target lowered to $46 from $52 at Deutsche Bank
04/05/22 UBS
Walgreens Boots Alliance price target lowered to $49 from $52 at UBS
04/01/22 Truist
Walgreens Boots Alliance price target lowered to $50 from $58 at Truist
WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

Hot Stocks
Pfizer, BioNTech announce data evaluating omicron-adapted vaccine candidates » 10:54
06/25/22
06/25
10:54
06/25/22
10:54
PFE

Pfizer

$51.60 /

+1.51 (+3.01%)

, BNTX

BioNTech

$133.98 /

+1.73 (+1.31%)

Pfizer (PFE) and BioNTech…

Pfizer (PFE) and BioNTech (BNTX) announced positive data evaluating the safety, tolerability, and immunogenicity of two omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 vaccine and a vaccine candidate targeting the spike protein of the Omicron BA.1 variant of concern. Data from the Phase 2/3 trial found that a booster dose of both omicron-adapted vaccine candidates elicited a substantially higher immune response against Omicron BA.1 as compared to the companies' current COVID-19 vaccine. The robust immune response was seen across two investigational dose levels, 30 microgram and 60 microgram. The Omicron adapted vaccine candidates studied in the Phase 2/3 trial in 1,234 participants 56 years of age and older elicited substantially higher neutralizing antibody responses against Omicron BA.1 when compared to the companies' current COVID-19 vaccine. The pre-specified criterion for superiority was measured by the ratio of neutralizing geometric mean titers with the lower bound of the 95% confidence interval greater than 1. The geometric mean ratios for the monovalent 30 microgram and 60 microgram vaccines compared to the current COVID-19 vaccine were 2.23 and 3.15, respectively. The GMRs for the bivalent 30 microgram and 60 microgram vaccines compared to the current COVID-19 vaccine were 1.56 and 1.97, respectively. The monovalent Omicron-adapted vaccine 30 microgram and 60 microgram achieved a lower bound 95% confidence interval for GMR of greater than1.5, consistent with the regulatory requirement of super superiority. Demonstration of superiority against omicron and safety are regulatory requirements for potential emergency use authorization of a variant-adapted vaccine. One month after administration, a booster dose of the omicron-adapted monovalent candidates increased neutralizing geometric mean titers against Omicron BA.1 13.5 and 19.6-fold above pre-booster dose levels, while a booster dose of the Omicron-adapted bivalent candidates conferred a 9.1 and 10.9-fold increase in neutralizing GMTs against Omicron BA.1. Both omicron-adapted vaccine candidates were well-tolerated in participants who received one or the other omicron-adapted vaccine. In a SARS-CoV-2 live virus neutralization assay tested on sera from participants over 56 years of age and older, sera efficiently neutralized BA.4/BA.5 with titers approximately 3-fold lower than BA.1. Pfizer and BioNTech will continue to collect additional study data on Omicron BA.4/BA.5 over the coming weeks.

ShowHide Related Items >><<
PFE Pfizer
$51.60 /

+1.51 (+3.01%)

BNTX BioNTech
$133.98 /

+1.73 (+1.31%)

PFE Pfizer
$51.60 /

+1.51 (+3.01%)

06/22/22 Piper Sandler
Enanta's lawsuit against Pfizer 'not surprising,' says Piper Sandler
06/13/22 Morgan Stanley
Moderna pediatric EUA vaccine briefing docs 'clean,' says Morgan Stanley
06/03/22 Oppenheimer
Turning Point Therapeutics downgraded to Perform from Outperform at Oppenheimer
05/31/22 Evercore ISI
Enanta upgraded to In Line from Underperform at Evercore ISI
BNTX BioNTech
$133.98 /

+1.73 (+1.31%)

04/12/22 H.C. Wainwright
BioNTech price target lowered to $298 from $339 at H.C. Wainwright
04/11/22 H.C. Wainwright
H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab
04/05/22 Canaccord
BioNTech price target lowered to $300 from $450 at Canaccord
PFE Pfizer
$51.60 /

+1.51 (+3.01%)

BNTX BioNTech
$133.98 /

+1.73 (+1.31%)

PFE Pfizer
$51.60 /

+1.51 (+3.01%)

BNTX BioNTech
$133.98 /

+1.73 (+1.31%)

PFE Pfizer
$51.60 /

+1.51 (+3.01%)

BNTX BioNTech
$133.98 /

+1.73 (+1.31%)

PFE Pfizer
$51.60 /

+1.51 (+3.01%)

BNTX BioNTech
$133.98 /

+1.73 (+1.31%)

Hot Stocks
Ionis announces presentation of Phase 2b data for chronic hepatitis B treatment » 10:49
06/25/22
06/25
10:49
06/25/22
10:49
IONS

Ionis Pharmaceuticals

$39.17 /

+0.14 (+0.36%)

, GSK

GSK plc

$43.69 /

+0.93 (+2.17%)

Ionis Pharmaceuticals…

Ionis Pharmaceuticals announced that GSK (GSK) presented results from an interim analysis of the Phase 2b B-Clear clinical study of bepirovirsen - formerly IONIS-HBVRx, an investigational antisense medicine for the treatment of patients with chronic hepatitis B virus. The data were presented in an oral late-breaker session at the European Association for the Study of the Liver's International Liver Congress 2022 in London, U.K. The final results from the study will be submitted for presentation at a scientific congress later this year, and for publication in a peer-reviewed journal. In the study, 28% of patients on standard of care, which is stable nucleoside/nucleotide analogue, and 29% of patients not on NA treatment, experienced a virologic response on 300 mg of bepirovirsen weekly, following 24 weeks of treatment. Virologic response is defined as serum/plasma levels of hepatitis B virus DNA and hepatitis B surface antigens below the lower limit of quantification. Up to 68% of patients on NA therapy and up to 65% of patients not on NA achieved HBsAg less than100 IU/mL at the end of treatment. End-of-treatment virologic responses were observed in patients with high or low baseline HBsAg levels, who were hepatitis B e-antigen negative or positive, and who were receiving NA treatment or not, indicating that bepirovirsen has the potential to treat broad segments of the CHB population. Durability of the responses is being assessed. Treatment-related serious adverse events were observed in less than 1% of patients receiving NA treatment and 1% of patients who were not on NA. SAEs were reported in 3% and 4% of patients receiving NA treatment and those who were not on NA, respectively. There were no clinically meaningful differences in adverse events across treatment arms in either trial. GSK is also exploring combinations of bepirovirsen and other therapeutic modalities in the following trials. Combination treatments could increase functional cure rates in more patients, thereby further reducing the global disease burden of CHB. Trials include:

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$39.17 /

+0.14 (+0.36%)

GSK GSK plc
$43.69 /

+0.93 (+2.17%)

IONS Ionis Pharmaceuticals
$39.17 /

+0.14 (+0.36%)

06/23/22 Citi
Citi adds AutoZone, Thermo Fisher, Ionis to 'Focus List'
06/21/22 Piper Sandler
Ionis told Piper eplontersen efficacy competitive with Amvuttra
06/10/22 Piper Sandler
Ionis Pharmaceuticals price target raised to $55 from $54 at Piper Sandler
05/05/22 Stifel
Ionis Pharmaceuticals price target raised to $33 from $31 at Stifel
GSK GSK plc
$43.69 /

+0.93 (+2.17%)

05/19/22 Deutsche Bank
GlaxoSmithKline price target raised to 1,750 GBp at Deutsche Bank
05/17/22 Roth Capital
Ideaya Biosciences price target raised to $46 from $42 at Roth Capital
05/13/22 Jefferies
Roche downgraded to Hold from Buy at Jefferies
04/29/22 Barclays
GlaxoSmithKline price target raised to 1,800 GBp from 1,775 GBp at Barclays
IONS Ionis Pharmaceuticals
$39.17 /

+0.14 (+0.36%)

GSK GSK plc
$43.69 /

+0.93 (+2.17%)

GSK GSK plc
$43.69 /

+0.93 (+2.17%)

IONS Ionis Pharmaceuticals
$39.17 /

+0.14 (+0.36%)

GSK GSK plc
$43.69 /

+0.93 (+2.17%)

GSK GSK plc
$43.69 /

+0.93 (+2.17%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.